Severe Asthma

Dupilumab significantly reduced asthma exacerbations and improved lung function within 2 weeks in children aged 6 to 11 years with uncontrolled moderate to severe asthma with evidence of type 2 inflammation.

A presenter at the American Thoracic Society International Conference provided an update on the latest clinical evidence from phase 3 studies of tezepelumab in a broad population of patients with severe asthma.

In adults with moderate to severe asthma, responsiveness to parenteral corticosteroids may be useful to predict lung function decline.

Patients with oral corticosteroid-dependent asthma treated with benralizumab achieved OCS elimination or reduction in those in whom adrenal insufficiency was detected, regardless of baseline eosinophil count, in the PONENTE trial.

After bronchial thermoplasty, airway smooth muscle mass was significantly decreased after 6 months in adults with severe asthma, according to results of the TASMA trial.

Previous and current use of hormonal contraceptives was associated with a small beneficial effect on asthma exacerbations in reproductive-aged, according to data published in Thorax.

AstraZeneca announced positive results from the NAVIGATOR phase 3 trial of tezepelumab, demonstrating a statistically significant and clinically meaningful reduction in exacerbations in patients with severe, uncontrolled asthma.

Adults who work permanent night shifts may have an increased risk for moderate to severe asthma, according to findings from an observational study published in Thorax.

Use of biologic therapies in patients with severe, uncontrolled asthma treated by subspecialists in the United States is common, according to data from the real-world, observational CHRONICLE study.

Benralizumab eliminated the use of maintenance oral corticosteroids in oral corticosteroid-dependent patients with severe asthma with a broad range of blood eosinophil counts, according to high-level results of the phase 3b PONENTE trial.